The division of monoclonal antibodies
Download
1 / 8

The Division of Monoclonal Antibodies - PowerPoint PPT Presentation


  • 258 Views
  • Updated On :

The Division of Monoclonal Antibodies. Kathleen A. Clouse, Ph.D., Director CTGTAC - July 26, 2007 . Mission of the DMA. … to ensure that safe, efficacious, and high quality

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'The Division of Monoclonal Antibodies' - jana


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
The division of monoclonal antibodies

The Division of Monoclonal Antibodies

Kathleen A. Clouse, Ph.D., Director

CTGTAC - July 26, 2007


Mission of the DMA

… to ensure that safe, efficacious, and high quality

monoclonal antibody and related products are available to the American people to diagnose, prevent and treat the illnesses that afflict them.

… to maintain and retain a diverse, knowledgeable,

scientifically based and dedicated staff actively

involved in research and regulatory review


Clinical Success of Monoclonal Antibodies

“Monoclonal antibodies now comprise the majority of recombinant proteins currently in the clinic, with more than 150 products in studies sponsored by companies located worldwide.”

Janice Reichert, Tufts University Center for the Study of Drug Development

Nature Biotechnology, September 2005



Dr. David Frucht

  • Established an independent research program to characterize

  • the activity of anthrax lethal toxin in vitro and in vivo

  • Reviews products for infectious diseases, including antibodies

  • under consideration for inclusion in the SNS under Emergency

  • Use Authorization

  • Reviews monoclonal antibodies or related molecules that

  • function as agonists or antagonists for hematologic indications

  • Participates in pre-approval inspections for MoAb products

  • Serves on working groups for guidance document development

  • (anthrax therapeutics development, drug-drug interactions)

  • Co-Chair, CDER/CBER Inter-Center Biotechnology Counter-

  • Terrorism Working Group

  • Chair, CMC session of the FDA-sponsored workshop on

  • “Immune Therapies for Anthrax Infection”


Dr. David Frucht

  • Board certified in Internal Medicine & Infectious Diseases

  • Performs weekly clinical rounds at NIH

  • Serves on Editorial Boards for The Journal of Immunology and

  • The Journalof Biological Chemistry

  • Awarded competitive HHS grants (2006 & 2007) and

  • CBER/FDA grants (2002 & 2003) for CBT research efforts

  • Duties as a Commissioned Officer, U.S. Public Health Service

  • - Incident Response Coordination Team, on-call every 5

  • months for deployment (six deployments in 3 years)

  • - Selected for the Physicians’ Professional Advisory Committee

  • to the Surgeon General


David Frucht, M.D.

Research Program Objectives

  • Identify biological markers for the activity of anthrax lethal toxin

  • (LT) in humans and animal models

  • Assess the biological significance of these markers in the

  • pathology of toxemia and/or anthrax infection

  • Establish the scientific basis for development of more relevant

  • bioassays to assess product potency

  • *Important for addressing issues relevant to seeking approval for

  • these products under the “Animal Rule” (i.e., efficacy testing in

  • animal models and not in humans)


David Frucht, M.D.

Research Program Milestones

  • Anthrax LT activates murine macrophages, leading to release of

  • IL-1b and IL-18 (J Biol Chem, 2004) - Identification of new

  • biomarkers & strain susceptibility factors

  • Anthrax LT targets human T cells, leading to a blockade in

  • proliferation and cytokine production (J Immunol, 2005) - A

  • pathogenic mechanism and basis for new bioassays

  • Anthrax LT blocks B cell proliferation and immunoglobulin

  • production (J Immunol, 2006) - A pathogenic mechanism and

  • basis for new bioassay


ad